Serialization deadlines in the United States and European Union have finally passed. Now what? Faced with complex region- and country-specific serialization mandates, pharmaceutical companies are questioning whether their current serialization software is the best long-term solution.
As the only company with the ability to provide true end-to-end traceability, from raw materials all the way up to the consumer, OPTEL is in a unique position to provide a better option. The good news is that your efforts up to this point are not lost. In fact, OPTEL’s approach to serialization platform conversion is centered on reusing any components that still provide value, while minimizing risk, cost and resource strain for your organization and your partners during the conversion process.
Read this white paper to learn more on OPTEL's three phases of conversion offering.